Overlap weighting analysis shows certolizumab pegol reduces anterior uveitis flares in high-risk axial spondyloarthritis, suggesting a promising treatment option.
This study supports the findings of C-VIEW and demonstrates the benefit of CZP over standard non-biologic treatment as a promising therapeutic option in reducing AAU flares among high-risk patients with axSpA.
No takes yet. Share an insight, caveat, or question.
Haroon et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: